Skip to content

D&A at other companies

Baxter International logo
Baxter InternationalBAX
$237M-4.0%
Boston Scientific logo
Boston ScientificBSX
$351M+8.0%
ITG
Integer HoldingsITGR
$35.01M+17.4%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%
Medtronic logo
MedtronicMDT
$716M-14.8%
Cytokinetics logo
CytokineticsCYTK
$3.38M+46.9%

Other financials

Income statement

See full
Revenue$199.4M+25.7%
Gross profit$141.4M+29.4%
Operating income-$16.2M+50.3%
Net income-$13.9M+54.6%
EPS (diluted)-$0.43+55.7%

Balance sheet

See full
Cash & equivalents$248.5M-35.2%
Total debt$79.0M-10.5%
Total equity$161.2M+86.0%
Total assets$1.0B+8.7%

Cash flow

See full
Operating cash flow-$26.2M-232%
CapEx$6.9M-26.7%
Free cash flow-$33.1M-91.1%

Valuation

See full
Market cap$3.62B+16.0%

Profitability

See full
Gross margin71%+1.6pp
Operating margin-5.5%-2.2pp
Net margin-7.3%-3.1pp
FCF margin2.4%

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.5×-0.5×
Current ratio5.2×-0.5×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: iRhythm Holdings, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRhythm Holdings, Inc. 's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRhythm Holdings, Inc. 's D&A?
iRhythm Holdings, Inc. (IRTC) reported D&A of $5.04M in Q1 2026.
How has iRhythm Holdings, Inc. 's D&A changed year-over-year?
iRhythm Holdings, Inc. 's D&A decreased by 3.2% year-over-year, from $5.21M to $5.04M.
What is the long-term trend for iRhythm Holdings, Inc. 's D&A?
Over 4 years (2021 to 2025), iRhythm Holdings, Inc. 's D&A has grown at a 20.5% compound annual growth rate (CAGR), from $9.84M to $20.74M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.